vimnerixin

Vimnerixin (AZD4721) is an orally active, potent, and selective small molecule antagonist of the CXC chemokine receptor type 2 (CXCR2), also known as the interleukin-8 receptor beta (IL-8Rβ). Developed by AstraZeneca, it was primarily investigated for the treatment of chronic obstructive pulmonary disease (COPD) by inhibiting neutrophil chemotaxis and reducing airway inflammation. Although it reached Phase II clinical development for COPD, AstraZeneca discontinued the program. The compound was subsequently licensed to Aristea Therapeutics (as RIST4721) for the treatment of inflammatory conditions such as palmoplantar pustulosis, but development was eventually halted due to safety concerns.

Other names

vimnerixin